JOHN WELBORN: Open Payments
NPI 1427496835 · GOUVERNEUR, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,056 in 36 payments from 8 companies in 2025. Trend: 2023 $533 · 2024 $642 · 2025 $1,056
Food & beverage: $1,056
| Company | Payments | Amount |
|---|---|---|
| Braeburn Inc. | 8 | $324 |
| Indivior Inc. | 17 | $201 |
| Madrigal Pharmaceuticals | 1 | $150 |
| AstraZeneca Pharmaceuticals LP | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 4 | $112 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $98 |
| Janssen Pharmaceuticals, Inc | 1 | $26 |
| E.R. Squibb & Sons, L.L.C. | 1 | $20 |
Products named: BRIXADI, SUBLOCADE, REZDIFFRA, CAPLYTA, ABILIFY ASIMTUFII, REXULTI, INVEGA SUSTENNA, ABILIFY MAINTENA.
Industry payments across NY — which companies pay providers there.
